Literature DB >> 21868473

Phospholipase A2 superfamily members play divergent roles after spinal cord injury.

Rubèn López-Vales1, Nader Ghasemlou, Adriana Redensek, Bradley J Kerr, Efrosini Barbayianni, Georgia Antonopoulou, Constantinos Baskakis, Khizr I Rathore, Violetta Constantinou-Kokotou, Daren Stephens, Takao Shimizu, Edward A Dennis, George Kokotos, Samuel David.   

Abstract

Spinal cord injury (SCI) results in permanent loss of motor functions. A significant aspect of the tissue damage and functional loss may be preventable as it occurs, secondary to the trauma. We show that the phospholipase A(2) (PLA(2)) superfamily plays important roles in SCI. PLA(2) enzymes hydrolyze membrane glycerophospholipids to yield a free fatty acid and lysophospholipid. Some free fatty acids (arachidonic acid) give rise to eicosanoids that promote inflammation, while some lysophospholipids (lysophosphatidylcholine) cause demyelination. We show in a mouse model of SCI that two cytosolic forms [calcium-dependent PLA(2) group IVA (cPLA(2) GIVA) and calcium-independent PLA(2) group VIA (iPLA(2) GVIA)], and a secreted form [secreted PLA(2) group IIA (sPLA(2) GIIA)] are up-regulated. Using selective inhibitors and null mice, we show that these PLA(2)s play differing roles. cPLA(2) GIVA mediates protection, whereas sPLA(2) GIIA and, to a lesser extent, iPLA(2) GVIA are detrimental. Furthermore, completely blocking all three PLA(2)s worsens outcome, while the most beneficial effects are seen by partial inhibition of all three. The partial inhibitor enhances expression of cPLA(2) and mediates its beneficial effects via the prostaglandin EP1 receptor. These findings indicate that drugs that inhibit detrimental forms of PLA(2) (sPLA(2) and iPLA2) and up-regulate the protective form (cPLA2) may be useful for the treatment of SCI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868473      PMCID: PMC3236632          DOI: 10.1096/fj.11-183186

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  47 in total

1.  Focal phospholipases A2 group III injections induce cervical white matter injury and functional deficits with delayed recovery concomitant with Schwann cell remyelination.

Authors:  W Lee Titsworth; Stephen M Onifer; Nai-Kui Liu; Xiao-Ming Xu
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

2.  Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord.

Authors:  S S Ousman; S David
Journal:  Glia       Date:  2000-03       Impact factor: 7.452

3.  Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes.

Authors:  Georgia Antonopoulou; Efrosini Barbayianni; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2008-11-01       Impact factor: 3.641

4.  Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.

Authors:  Constantinos Baskakis; Victoria Magrioti; Naomi Cotton; Daren Stephens; Violetta Constantinou-Kokotou; Edward A Dennis; George Kokotos
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.

Authors:  Athena Kalyvas; Constantinos Baskakis; Victoria Magrioti; Violetta Constantinou-Kokotou; Daren Stephens; Rubèn López-Vales; Jian-Qiang Lu; V Wee Yong; Edward A Dennis; George Kokotos; Samuel David
Journal:  Brain       Date:  2009-02-13       Impact factor: 13.501

6.  Arachidonyl trifluoromethyl ketone is neuroprotective after spinal cord injury.

Authors:  Wenlong Huang; Amar Bhavsar; Rachael E Ward; Jodie C E Hall; John V Priestley; Adina T Michael-Titus
Journal:  J Neurotrauma       Date:  2009-08       Impact factor: 5.269

7.  A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury.

Authors:  W L Huang; V R King; O E Curran; S C Dyall; R E Ward; N Lal; J V Priestley; A T Michael-Titus
Journal:  Brain       Date:  2007-09-27       Impact factor: 13.501

8.  Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury.

Authors:  Rubèn López-Vales; Xavier Navarro; Takao Shimizu; Constantinos Baskakis; George Kokotos; Violetta Constantinou-Kokotou; Daren Stephens; Edward A Dennis; Samuel David
Journal:  Brain       Date:  2008-08-21       Impact factor: 13.501

9.  Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death.

Authors:  W Lee Titsworth; Xiaoxin Cheng; Yan Ke; Lingxiao Deng; Kenneth A Burckardt; Chris Pendleton; Nai-Kui Liu; Hui Shao; Qi-Lin Cao; Xiao-Ming Xu
Journal:  Glia       Date:  2009-11-01       Impact factor: 7.452

10.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Rene O Sanchez-Mejia; John W Newman; Sandy Toh; Gui-Qiu Yu; Yungui Zhou; Brian Halabisky; Moustapha Cissé; Kimberly Scearce-Levie; Irene H Cheng; Li Gan; Jorge J Palop; Joseph V Bonventre; Lennart Mucke
Journal:  Nat Neurosci       Date:  2008-10-19       Impact factor: 24.884

View more
  20 in total

Review 1.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

2.  Arachidonic acid closes innexin/pannexin channels and thereby inhibits microglia cell movement to a nerve injury.

Authors:  Stuart E Samuels; Jeffrey B Lipitz; Junjie Wang; Gerhard Dahl; Kenneth J Muller
Journal:  Dev Neurobiol       Date:  2013-06-18       Impact factor: 3.964

3.  Analyses of Calcium-Independent Phospholipase A2beta (iPLA2β) in Biological Systems.

Authors:  S E Barbour; S Ramanadham
Journal:  Methods Enzymol       Date:  2016-10-18       Impact factor: 1.600

4.  cPLA2α-/- sympathetic neurons exhibit increased membrane excitability and loss of N-Type Ca2+ current inhibition by M1 muscarinic receptor signaling.

Authors:  Liwang Liu; Joseph V Bonventre; Ann R Rittenhouse
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

5.  Dietary omega-3 polyunsaturated fatty acids improve the neurolipidome and restore the DHA status while promoting functional recovery after experimental spinal cord injury.

Authors:  Johnny D Figueroa; Kathia Cordero; Miguel S Llán; Marino De Leon
Journal:  J Neurotrauma       Date:  2013-02-06       Impact factor: 5.269

6.  Beneficial effects of IL-37 after spinal cord injury in mice.

Authors:  Marina Coll-Miró; Isaac Francos-Quijorna; Eva Santos-Nogueira; Abel Torres-Espin; Philip Bufler; Charles A Dinarello; Rubèn López-Vales
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 7.  Liberating Chiral Lipid Mediators, Inflammatory Enzymes, and LIPID MAPS from Biological Grease.

Authors:  Edward A Dennis
Journal:  J Biol Chem       Date:  2016-08-23       Impact factor: 5.157

Review 8.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases.

Authors:  Sasanka Ramanadham; Tomader Ali; Jason W Ashley; Robert N Bone; William D Hancock; Xiaoyong Lei
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

9.  Activation of Lysophosphatidic Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord Injury.

Authors:  Eva Santos-Nogueira; Clara López-Serrano; Joaquim Hernández; Natalia Lago; Alma M Astudillo; Jesús Balsinde; Guillermo Estivill-Torrús; Fernando Rodriguez de Fonseca; Jerold Chun; Rubèn López-Vales
Journal:  J Neurosci       Date:  2015-07-15       Impact factor: 6.167

Review 10.  Neutrophil, Extracellular Matrix Components, and Their Interlinked Action in Promoting Secondary Pathogenesis After Spinal Cord Injury.

Authors:  Sonam Dolma; Hemant Kumar
Journal:  Mol Neurobiol       Date:  2021-06-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.